Importance of increased ultrafiltration volume and impact on mortality: sepsis and cytokine story and the role of continuous veno-venous haemofiltration
C. Ronco et al., Importance of increased ultrafiltration volume and impact on mortality: sepsis and cytokine story and the role of continuous veno-venous haemofiltration, CURR OP NEP, 10(6), 2001, pp. 755-761
While in end-stage renal disease dialysis dose correlates with morbidity an
d mortality, this correlation is less evident in acute renal failure. In sp
ite of a poor literature in the field, a few recent papers seem to suggest
that an increase in treatment dose may result in an improved Outcome Of cri
tically ill patients affected by acute renal failure. This improvement appe
ars to plateau at a certain level of dialysis dose in the general populatio
n while, in septic patients, the correlation between treatment dose and out
come continues linearly. These results suggest that, while the 'renal dose'
of renal replacement therapy has a threshold beyond which further improvem
ents cannot be expected, the 'septic dose' of renal replacement therapy is
probably higher and may provide benefits beyond simple blood purification f
rom uremic toxins. This approach is in agreement with the recently proposed
'peak concentration hypothesis', which suggests that sepsis may derive fro
m a complete derangement of the immunological response, featuring simultane
ous peaks of pro- and anti-inflammatory mediators. This would explain the s
ystemic inflammatory syndrome and the cell hyporesponsiveness of the septic
patient and, at the same time, would explain the beneficial effects of new
therapies such as high volume hemofiltration, coupled plasmafiltration ads
orption and dialysis with hyperpermeable membranes. These therapies could b
e able to reduce the peaks of the pro- and anti-inflammatory substances cir
culating during the syndrome, leading to a less severe degree of inflammati
on and immunodepression. Curr Opin Nephrol Hypertens 10:755-761. (C) 2001 L
ippincott Williams & Wilkins.